Skip to content Skip to footer
Subscribe Now
AstraZeneca & Ionis
News

AstraZeneca and Ionis’ Wainzua (Eplontersen) Receives the EC’s Approval to Treat Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Shots:The EC has approved Wainzua to treat ATTRv-PN (stage 1/2 polyneuropathy) in adults pts based on P-III (NEURO-TTRansform) trial assessing eplontersen vs external PBO over 66wks., with follow-up to Wk. 85 & an end-of-trial evaluation. Eligible pts could then enter an ongoing OLE study Trial showed sustained benefits in co-1EPs of serum transthyretin…
March 11, 2025

Read more

Viewpoints_Mina Makar
VIEWPOINTS

Curbing Misfolded TTR with RNA Therapy: Mina Makar from AstraZeneca in a Stimulating Conversation with PharmaShots

Shots: Misfolded TTR can lead to chronic conditions like ATTRv-PN or ATTR-CM. AstraZeneca’s Wainua (eplontersen) is a once-a-month RNA-targeted medication that suppresses TTR production Mina Makar SVP and Commerical Lead of the Global Cardiovascular, Renal, and Metabolism (CVRM), Biopharmaceuticals Business Unit at AstraZeneca, sheds light on eplontersen and its ongoing P-III clinical trial on ATTR-CM …
February 17, 2025

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]